COVID-19 Update: All AMP Locations are open, see how we are offering safe in person care and virtual visits. Click here to Learn more about Virtual Care Options.

Click here for additional COVID-19 Information

Non-Discrimination Notice

Merck 921

Merck 921- A Phase 3, Randomized, Double-Blind study of Pemrbrolizumab plus Docetaxel plus prednisone versus Placebo plus Docetaxel Plus Prednisone.

Population:

Chemo Naïve MCRPC who have progressed on NHA.

Sponsored by: Merck
Enrollment: Open

Please contact one of our Clinical Research Coordinators today to find out more information if you are interested in this trial.

Research Department (315) 478-4185, option 3